Humana Inc. (NYSE:HUM) Position Boosted by Asset Dedication LLC

Asset Dedication LLC boosted its holdings in Humana Inc. (NYSE:HUM) by 73.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 800 shares of the insurance provider’s stock after purchasing an additional 339 shares during the quarter. Asset Dedication LLC’s holdings in Humana were worth $203,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of HUM. Creative Financial Designs Inc. ADV increased its position in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the period. Atwood & Palmer Inc. bought a new position in shares of Humana in the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Humana during the 3rd quarter valued at $31,000. Your Advocates Ltd. LLP grew its holdings in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares during the period. Finally, LRI Investments LLC grew its stake in shares of Humana by 1,021.4% in the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock worth $50,000 after purchasing an additional 143 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on HUM shares. Stephens reaffirmed an “equal weight” rating and set a $250.00 target price on shares of Humana in a research report on Wednesday, October 9th. Leerink Partners downgraded shares of Humana from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Wells Fargo & Company reduced their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and lowered their price objective for the company from $519.00 to $253.00 in a report on Monday, October 7th. Finally, Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $297.68.

Humana Price Performance

NYSE:HUM opened at $294.18 on Thursday. The company’s 50-day moving average price is $275.44 and its two-hundred day moving average price is $303.14. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The firm has a market cap of $35.42 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. On average, equities analysts anticipate that Humana Inc. will post 16.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.